SCHEMBL6441534

SCHEMBL6441534

C[C@@H]1CN(C(=O)c2ccccn2)CCN1C(=O)C(=O)c1c[nH]c2c(C(=N)NO)ccc(F)c12

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 5/20 0.51
CYP2D6 P10635 4/20 0.51
CYP2C9 P11712 4/20 0.51
CYP3A4 P08684 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
GHSR Q92847 5/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
CPS1 P31327 1/20 0.35
PARP1 P09874 1/20 0.34
DPP4 P27487 1/20 0.33
DPP9 Q86TI2 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441531 1.00 CYP2C19 (0.51) CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL6445636 0.90 CYP2C19 (0.51) CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL7073321 0.90 CYP2C19 (0.51) CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL6447630 0.89 CYP2D6 (0.58) CYP2C19CYP2D6CYP2C9CYP3A4GHSR
SCHEMBL6447634 0.89 CYP2D6 (0.58) CYP2C19CYP2D6CYP2C9CYP3A4GHSR
SCHEMBL6443079 0.88 L3MBTL1 (0.46) CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL6441429 0.88 CYP2C19 (0.49) CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL1763119 0.85 CYP2C19 (0.51) CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL2633280 0.85 CYP2C19 (0.51) CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2
SCHEMBL6471735 0.84 CYP2D6 (0.53) CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299382-B1 COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2005-09-21 EP claimed
US-6573262-B2 Compounds for treating mammals infected with HIV virus BRISTOL-MYERS SQIBB COMPANY 2003-06-03 US claimed
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) 2003-04-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069245-A1 Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives IDO1, IDO2, ITPA CYP2C19 1624/4885CYP2D6 831/4885CYP2C9 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.